1. Bloch surface wave label-free and fluorescence platform for the detection of VEGF biomarker in biological matrices
   Riccardo Rizzo et al, 2018, Sensors and Actuators B: Chemical CrossRef
2. Markers to Predict the Efficacy of Bevacizumab in the Treatment of Metastatic Colorectal Cancer
   Umut Varol et al, 2014, Tumori Journal CrossRef
3. Genetic variation determines VEGF-A plasma levels in cancer patients
   Federico Innocenti et al, 2018, Sci Rep CrossRef
4. Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review
   Juan Ruiz-Bañobre et al, 2019, JCO Precision Oncology CrossRef
5. null
   E. Gabriela Chiorean et al, 2015 CrossRef
6. Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients
   Fausto Petrelli et al, 2015, Med Oncol CrossRef
7. Advances and perspectives of colorectal cancer stem cell vaccine.
   Mei Guo et al, 0 CrossRef
8. Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment
   Sinead A. Noonan et al, 2018, Oncotarget CrossRef
9. Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer
   Simona Delle Monache et al, 2020, J Cancer Res Clin Oncol CrossRef
10. Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes
    Ruszkowska-Ciastek Barbara et al, 2020, JCM CrossRef
11. Profiles of Endoglin and Vascular Endothelial Growth Factor Based on Staging and Histological Grading of Colorectal Cancer and Their Relationship with Bevacizumab Therapy
    Rahmawati Minhajat et al, 2021, Journal of Coloproctology CrossRef
12. The cancer angiogenesis co-culture assay: In vitro quantification of the angiogenic potential of tumoroids
    Sarah Line Bring Truelsen et al, 2021, PLoS ONE CrossRef
13. VEGF-A promotes the motility of human melanoma cells through the VEGFR1–PI3K/Akt signaling pathway
    Koichi Koizumi et al, 2022, In Vitro Cell.Dev.Biol.-Animal CrossRef
14. Targeting angiogenesis in oncology, ophthalmology and beyond
    Yihai Cao et al, 2023, Nat Rev Drug Discov CrossRef
15. Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
    Keiko Tanimura et al, 2023 CrossRef
16. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study
    Satoshi Yuki et al, 2024, Clinical Colorectal Cancer CrossRef
17. The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer.
    Domenico Ribatti et al, 2021, Cancers (Basel) CrossRef
18. Upshot of Some Bioactive Compounds on Angiogenesis in Retinal Pigment Epithelial Cells
    Serkan Sen et al, 2025, J Cellular Molecular Medi CrossRef